Tirzepatide: difference between revisions
Diff·revision 16 → 17·07:22, 8 Feb 2025
Difference between revision 16 and revision 17 of Tirzepatide. 5 lines changed; the page grew by 845 bytes.
| Revision 16 — 06:26, 21 Jan 2025 TimelineTiernan (talk) add CAS number, sourced 5,389 bytes ±0 | Revision 17 — 07:22, 8 Feb 2025 IcodecIndra (talk) expand §Adverse effects and tolerability 6,234 bytes +845 | ||
|---|---|---|---|
| 46 | Discontinuation for adverse events across the programme ran at roughly 4–7% on active treatment, comparable with other agents in the field despite the larger effect size.{{r|jastreboff2022}} | 46 | Discontinuation for adverse events across the programme ran at roughly 4–7% on active treatment, comparable with other agents in the field despite the larger effect size.{{r|jastreboff2022}} |
| 47 | 47 | ||
| + | 48 | == Adverse effects and tolerability == | |
| + | 49 | The adverse-effect profile is qualitatively that of the [[GLP-1 receptor agonist|GLP-1 class]]: nausea, vomiting, diarrhoea and constipation, concentrated in escalation and dose-related. Reported frequencies at 15 mg are broadly similar to those for semaglutide 2.4 mg despite the greater weight effect, which is one of the more interesting observations in the programme and is not fully explained.{{r|jastreboff2022}} | |
| + | 50 | ||
| + | 51 | Gallbladder events, injection-site reactions and a small resting heart-rate increase are all reported. The label carries the class contraindication in personal or family history of medullary thyroid carcinoma. Hypoglycaemia is uncommon in monotherapy and becomes relevant when the drug is combined with insulin or a sulfonylurea, in which case the background agent is usually reduced. | |
| + | 52 | ||
| 48 | == References == | 53 | == References == |
| 49 | {{reflist}} | 54 | {{reflist}} |